COMMUNIQUÉS West-GlobeNewswire

Bionano Adjourns Special Meeting of Stockholders to November 27, 2024

31/10/2024 - 13:10

Special Meeting of Stockholders Adjourned Due to Lack of Quorum SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of [...]

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

31/10/2024 - 13:08

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for [...]

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

31/10/2024 - 13:05

Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures for those who [...]

MaxCyte to Participate in Two Upcoming Investor Conferences

31/10/2024 - 13:05

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Standard BioTools to Participate in Upcoming Investor Conferences

31/10/2024 - 13:01

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of [...]

Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions

31/10/2024 - 13:00

Nanox AI’s Solutions selected for Special Mention on annual list recognizing the most impactful new products and ideas PETACH TIKVA, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company [...]

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

31/10/2024 - 13:00

Partnership to Combine AbbVie’s Oncology Expertise with EvolveImmune’s Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn [...]

Oxford BioTherapeutics to Present at World ADC Conference 2024

31/10/2024 - 13:00

CMO Dr. Harald Haeske to present innovative approaches for combining ADCs with immune checkpoint inhibitors to enhance therapeutic efficacy OBT will also present insights on its target discovery platform, OGAP®-Verify, [...]

Evaxion announces business update and third quarter 2024 financial results

31/10/2024 - 13:00

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces [...]

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award

31/10/2024 - 13:00

Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging SEATTLE, Oct. 31, 2024 ( [...]

Reviva to Participate in the UBS Global Healthcare Conference

31/10/2024 - 13:00

CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)

31/10/2024 - 13:00

Data show SBT101 effectively delivered a functional copy of the ABCD1 gene to spinal cord tissues with resultant protein expression, addressing the underlying cause of disease and improving function in preclinical [...]

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

31/10/2024 - 13:00

Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023. Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the [...]

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

31/10/2024 - 13:00

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to [...]

Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer

31/10/2024 - 13:00

Two Key Executive Hires for Organizational Capabilities and Growth CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company [...]

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

31/10/2024 - 13:00

WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration [...]

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

31/10/2024 - 13:00

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical [...]

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

31/10/2024 - 13:00

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

31/10/2024 - 11:23

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]